News and Conferences

Newsletters

• Read About Our Animal Health Services
  2025-02-07
• Experimental Autoimmune Encephalomyelitis (EAE): Maximising The Therapeutic Efficacy of Fingolimod
  2024-12-17
• Cross-Species Epilepsy Research: Revealing the Potential of the Zebrafish Model
  2024-12-12
• Monoamine depletion to induce chronic allodynia and behavioural changes: a model of fibromyalgia
  2024-10-16
• Take your R&D pipeline into the AI era with Moseq (Motion Sequencing), our new behavioural machine-learning assay!
  2024-08-22
• Canine Microbiome
  2024-07-23
• Oral Health: Not just for Humans
  2024-06-20
• Novel Object Recognition: A Reliable Assay for Addressing Cognitive Impairments in Schizophrenia
  2024-06-11
• Pre-pulse Inhibition: A Promising Screening Tool for Novel Compounds
  2024-05-16
• Natural and induced models of osteoarthritis in Beagle dogs
  2024-04-30
• Utilizing Rapid Screening Tests to Assess the Antidepressant Potential of Psychedelic Analogues
  2024-04-16
• Long-term antidepressant effect of ketamine and psilocybin in the Chronic Social Defeat stress model
  2024-03-21
• Diabetes and Metabolic Syndrome
  2024-03-14
• Transpharmation's Animal Health Services
  2024-02-29
• Longevity Research Goes to the Dogs
  2024-02-20
• Transpharmation's Cutting-Edge Antiepileptic Drug Screening: A Global Solution for Advancing Epilepsy Research
  2024-02-01
• PTZ-treated Zebrafish provide a high throughput platform for screening novel anti-epileptic drugs
  2024-01-25
• Beyond Seizures: Epilepsy Comorbidities Explored in Mouse Kindling Studies
  2024-01-18
• Novelty-suppressed feeding and novelty-induced hypophagia: exploring sex differences and response to diazepam in C57BL/6J mice.
  2023-12-14
• Development & validation of intrathecal dosing in rats and mice
  2023-12-05
• Transpharmation's Mouse-EEG capability reveals cross-species effects of novel antidepressants ketamine and psilocybin
  2023-11-22
• Oral Health: Not just for Humans...
  2023-10-31
• Accelerate Your Diabetes Drug Development with Transpharmation's Dog Diabetes Models
  2023-10-18
• Introducing our new data analysis service for tremor-plate signals!
  2023-09-29
• Introducing the Scn1a mutant mouse model of Dravet Syndrome at Transpharmation
  2023-09-21
• New validated pre-clinical model to assess treatments for post-surgical pain
  2023-08-31
• Experimental Autoimmune Encephalomyelitis; Modelling Multiple Sclerosis and Beyond
  2023-08-21
• New Preclinical Models of Migraine for Assessment of Rescue and Preventive Analgesic Treatments
  2023-08-01
• Do Your Compounds Exhibit Anti-Inflammatory Compounds
  2023-07-17
• Profile your anti-inflammatory compounds in primary human immune cells
  2023-06-28
• New EEG services from Transpharmation. Read on for results...
  2023-06-14
• Accelerate your Drug Discovery Research. Proven results, fast and cost effective
  2023-06-07
• Urgent Treatments Needed for Parkinson's Disease
  2023-05-16
• Poor bioavailability, is the liver or intestine to blame?
  2023-05-03
• Laser Doppler; new validated protocols revealed.
  2023-04-21
• Epilepsy models leading the way. Read on for results.
  2023-03-27
• Profiling anti-inflammatory drugs; from rodent to human
  2023-03-02
• The Mismatch Negativity Challenge
  2023-01-25
• Accelerate your drug discovery research. Proven science based results cost-effectively.
  2022-12-20
• Anxiety. Three preclinical tests; data revealed...
  2022-12-12
• Seven new posters, presented at SfN, now available to view.
  2022-11-23
• Name change announcement! News from the CEO.
  2022-11-04
• Chronic fatigue: different etiologies influence translational models
  2022-10-18
• Seven new translational studies to share with you at this year's SfN event. Read on for poster titles and contact details.
  2022-10-03
• Translational value increased with non-evoked pain measures.
  2022-09-21
• Rapid access to PK non-rodent studies. Leading expertise.
  2022-09-01
• Essential tremor research
  2022-08-19
• Can a psychedelic experience be modelled in rats?
  2022-08-01
• Gender Differences in Pain. New research revealed!
  2022-06-30
• New data on the effect of single dose psilocybin!
  2022-05-25
• From ketamine to psychedelics, join our webinar starting tomorrow!
  2022-05-09
• Long term delayed effects of psychedelics in preclinical models. Trailblazing results revealed!
  2022-04-05
• Accreditation awarded with flying colours
  2022-03-01
• Breaking news! Merger announcement between Transpharmation and InterVivo Solutions.
  2022-02-08
• Take a look! New posters, nine therapeutic areas available to view now.
  2021-12-01
• Nine new compelling studies to be revealed at SfN21!
  2021-11-03
• Can changes in EEG improve neuropathic pain treatments?
  2021-10-11
• 40Hz ASSR: sounds that change our thoughts about schizophrenia
  2021-08-31
• Clerkenwell Health and Transpharmation combine lab and human trials for psilocybin
  2021-08-09
• Translational endpoints for preclinical pain - improving your chances.
  2021-07-01
• Transpharmation aims for global standard. Let's talk about lab sustainability.
  2021-06-02
• Targeting the unmet medical need in Parkinson's Disease - the fastest growing neurological disorder.
  2021-04-15
• Psilocybin: the power of mental reorganisation
  2020-12-06
• Expansion to world class premises
  2020-11-04
• Multiple therapeutic indications
  2020-10-05
• Focus on pain
  2020-09-04
• Gene therapies for body and brain in Duchenne Muscular Dystrophy, progress moves forward.
  2020-03-08
• Announcing Transpharmation Poland!
  2020-02-08